Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sanofi Curbs Supply of Ultra-Fast Acting Insulin Biosimilars in Japan
Sanofi has started curtailing its shipments of ultra-fast acting insulin analogs in Japan, including Insulin Lispro BS Injection SoloStar HU “Sanofi”, a biosimilar version of Eli Lilly’s Humalog (insulin lispro), as it foresees demand that outstrips its planned supply volumes.…
To read the full story
Related Article
BUSINESS
- Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
- Takeda CEO Pulls in 2.3 Billion Yen in FY2025
June 18, 2026
- AZ, Kyoto Ink Pact to Promote NCD Prevention, Early Detection
June 18, 2026
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
June 17, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…